MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, wishes to address its shareholders in response to a press release issued today by Future Pak, LLC (“Future Pak”) regarding its proposals to acquire the Company. The Company believes its shareholders should be aware of the following: In August 2024, the Company received a first unsolicited non-binding proposal from Future Pak to acq ...

Core Viewpoint - Theratechnologies Inc. is currently in discussions with Future Pak, LLC regarding a potential acquisition, with a special committee formed to evaluate the proposals and ensure the best interests of the Company and its stakeholders are prioritized [1][2]. Group 1: Acquisition Proposals - Future Pak has conducted extensive due diligence on Theratechnologies and negotiations for a definitive agreement are ongoing [1]. - A "go shop" provision is expected to be included in any definitive agreement, allowing Theratechnologies to engage with other potential acquirers after the agreement is signed [1]. - The Company received an unsolicited non-binding acquisition proposal from Future Pak in August 2024, which was rejected due to unattractive terms [6]. Group 2: Special Committee and Advisors - A special committee of independent directors has been established to review acquisition proposals and determine the best course of action for the Company [2]. - The special committee is being advised by Barclays Capital Inc. as a financial advisor and Fasken Martineau DuMoulin LLP as external legal counsel [2]. Group 3: Future Engagements - Future Pak's proposals were made without completing due diligence beyond publicly available information, and the Company has indicated that Future Pak will have future opportunities to engage with them [6]. - The Company does not intend to provide further updates on the acquisition discussions to allow the special committee to focus on its mandate [3].

Core Insights - The FDA has approved Theratechnologies' Prior Approval Supplement (PAS) for EGRIFTA SV®, allowing unrestricted distribution and removing previous supply uncertainties [1][2][3] - The new formulation, EGRIFTA WR™, has also been approved by the FDA and is set to replace EGRIFTA SV® in the U.S. market [2][3] Company Overview - Theratechnologies Inc. is a commercial-stage biopharmaceutical company focused on innovative therapies, particularly for HIV-related conditions [1][8] - The company aims to improve patient experience with the new EGRIFTA WR™ formulation, which is designed to be more convenient [3] Product Information - EGRIFTA SV® (tesamorelin for injection) is the only FDA-approved treatment for reducing excess abdominal fat in adults with HIV and lipodystrophy [1][3] - Tesamorelin acts as a growth hormone-releasing factor (GHRF) analog, stimulating the production and release of endogenous growth hormone [3] Regulatory Developments - The approval of the PAS eliminates the need for discretionary product release, enabling the company to resume regular distribution of EGRIFTA SV® [2] - The transition to EGRIFTA WR™ is anticipated to enhance patient compliance and overall treatment experience [3]